Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $3,249,948.00 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Elizabeth Hougen sold 49,800 shares of the business’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $65.26, for a total value of $3,249,948.00. Following the completion of the sale, the executive vice president owned 110,500 shares of the company’s stock, valued at approximately $7,211,230. This trade represents a 31.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ionis Pharmaceuticals Stock Up 1.1%

NASDAQ IONS opened at $69.15 on Friday. The business has a fifty day moving average price of $52.25 and a two-hundred day moving average price of $40.58. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $69.25. The stock has a market capitalization of $11.02 billion, a PE ratio of -37.58 and a beta of 0.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.51. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The firm had revenue of $452.00 million during the quarter, compared to analysts’ expectations of $270.90 million. During the same period in the prior year, the company earned ($0.45) earnings per share. The company’s quarterly revenue was up 100.9% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Institutional Trading of Ionis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of IONS. California State Teachers Retirement System increased its holdings in Ionis Pharmaceuticals by 6.1% in the fourth quarter. California State Teachers Retirement System now owns 133,902 shares of the company’s stock valued at $4,681,000 after purchasing an additional 7,722 shares during the period. GAMMA Investing LLC increased its holdings in Ionis Pharmaceuticals by 3,786.5% in the first quarter. GAMMA Investing LLC now owns 28,993 shares of the company’s stock valued at $961,000 after purchasing an additional 28,247 shares during the period. Fifth Third Bancorp increased its holdings in Ionis Pharmaceuticals by 4.8% in the first quarter. Fifth Third Bancorp now owns 9,989 shares of the company’s stock valued at $301,000 after purchasing an additional 458 shares during the period. Exchange Traded Concepts LLC grew its holdings in Ionis Pharmaceuticals by 1,722.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 3,244 shares of the company’s stock worth $98,000 after acquiring an additional 3,066 shares during the period. Finally, Moisand Fitzgerald Tamayo LLC acquired a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $151,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Stifel Nicolaus set a $43.00 target price on Ionis Pharmaceuticals in a research note on Thursday, August 21st. Raymond James Financial set a $75.00 target price on Ionis Pharmaceuticals and gave the stock a “strong-buy” rating in a research note on Monday, September 22nd. The Goldman Sachs Group upgraded Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Friday, September 26th. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 16th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $73.88.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.